title: CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour.
abstract: Some 3-10% of Caucasians are deficient in CYP2D6 metabolism (poor metabolizers), due to inheritance of two defective alleles, whereas amplification of the CYP2D6 gene results in ultrarapid metabolism in 1-2% of Caucasian populations. To examine the possible association between CYP2D6 polymorphism and individual smoking behaviour, we analysed the prevalence of CYP2D6 genotypes among 292 long-term heavy smokers, 382 individuals with more variable smoking histories, and 302 never-smokers. The prevalence of ultrarapid metabolizers in heavy smokers (7.9%) was twofold compared to individuals with variable smoking habits (3.7%; odds ratio 2.3, 95% confidence interval 1.2-4.4), and fourfold compared with never-smokers (2.0%) (odds ratio 4.2, 95% confidence interval 1.8-9.8). The frequency of poor metabolizer genotype was approximately 2%, in each smoker group. However, when men and women were studied separately, the prevalence of poor metabolizer genotype was higher in male never-smokers (3.6%) than in variable smokers (2.7%) and heavy smokers (2.2%). Moreover, a trend test, adjusted by age, gender and cancer status, revealed a significant trend for the increased tobacco usage with increased metabolic capacity. Our results are in agreement with the assumption that increased CYP2D6 activity may contribute to the probability of being addicted to smoking.
authors.affiliation: Finnish Institute of Occupational Health, Helsinki.
authors.forename: S T
authors.initials: ST
authors.lastname: Saarikoski
authors.forename: F
authors.initials: F
authors.lastname: Sata
authors.forename: K
authors.initials: K
authors.lastname: Husgafvel-Pursiainen
authors.forename: M
authors.initials: M
authors.lastname: Rautalahti
authors.forename: J
authors.initials: J
authors.lastname: Haukka
authors.forename: O
authors.initials: O
authors.lastname: Impivaara
authors.forename: J
authors.initials: J
authors.lastname: Järvisalo
authors.forename: H
authors.initials: H
authors.lastname: Vainio
authors.forename: A
authors.initials: A
authors.lastname: Hirvonen
mesh_terms: D017677:Age Distribution; D000368:Aged; D000483:Alleles; D001521:Behavior Therapy / Q000379:methods; D016739:Behavior, Addictive / Q000453:epidemiology / Q000235:genetics* / Q000378:metabolism*; D015139:Blotting, Southern; D015897:Comorbidity; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics* / Q000378:metabolism; D005260:Female; D005387:Finland / Q000453:epidemiology; D005787:Gene Frequency / Q000235:genetics; D005838:Genotype; D006801:Humans; D008175:Lung Neoplasms / Q000453:epidemiology; D008214:Lymphocytes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D016017:Odds Ratio; D017678:Sex Distribution; D012907:Smoking / Q000453:epidemiology / Q000235:genetics* / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology
chemical_list: D019389:Cytochrome P-450 CYP2D6